Which has higher earnings and valuation, EXEL or NTRA?

Exelixis has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 5.90 $782.57M $3.18 17.38 Natera $2.31B 21.17 -$208.16M -$1.36 N/A

Is EXEL or NTRA more profitable?

Exelixis has a net margin of 35.33% compared to Natera's net margin of -7.11%. Exelixis' return on equity of 42.17% beat Natera's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Natera -7.11% -11.38% -7.87%

Does the media refer more to EXEL or NTRA?

In the previous week, Natera had 22 more articles in the media than Exelixis. MarketBeat recorded 47 mentions for Natera and 25 mentions for Exelixis. Exelixis' average media sentiment score of 1.34 beat Natera's score of 1.28 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 20 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Natera 36 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media favor EXEL or RVMD?

In the previous week, Revolution Medicines had 20 more articles in the media than Exelixis. MarketBeat recorded 45 mentions for Revolution Medicines and 25 mentions for Exelixis. Exelixis' average media sentiment score of 1.34 beat Revolution Medicines' score of 0.91 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 20 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 27 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 3 Very Negative mention(s) Positive

Which has better earnings and valuation, BIIB or EXEL?

Biogen has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.31 $1.29B $5.65 39.20 Exelixis $2.32B 5.90 $782.57M $3.18 17.38

Is BIIB or EXEL more profitable?

Exelixis has a net margin of 35.33% compared to Biogen's net margin of 8.32%. Exelixis' return on equity of 42.17% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Exelixis 35.33% 42.17% 31.76%

Does the media prefer BIIB or EXEL?

In the previous week, Biogen had 13 more articles in the media than Exelixis. MarketBeat recorded 38 mentions for Biogen and 25 mentions for Exelixis. Exelixis' average media sentiment score of 1.34 beat Biogen's score of 1.23 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 29 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 20 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALNY or EXEL?

In the previous week, Alnylam Pharmaceuticals had 2 more articles in the media than Exelixis. MarketBeat recorded 27 mentions for Alnylam Pharmaceuticals and 25 mentions for Exelixis. Exelixis' average media sentiment score of 1.34 beat Alnylam Pharmaceuticals' score of 1.18 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 21 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Exelixis 20 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, BNTX or EXEL?

Exelixis has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioNTech $3.25B 8.68 -$1.29B -$7.83 N/A Exelixis $2.32B 5.90 $782.57M $3.18 17.38

Is BNTX or EXEL more profitable?

Exelixis has a net margin of 35.33% compared to BioNTech's net margin of -63.54%. Exelixis' return on equity of 42.17% beat BioNTech's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -63.54% -6.86% -6.00% Exelixis 35.33% 42.17% 31.76%

Does the media prefer BNTX or EXEL?

In the previous week, Exelixis had 11 more articles in the media than BioNTech. MarketBeat recorded 25 mentions for Exelixis and 14 mentions for BioNTech. Exelixis' average media sentiment score of 1.34 beat BioNTech's score of 0.05 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Exelixis 20 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Exelixis (EXEL) Competitors

$55.26 -0.84 (-1.50%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$53.60 -1.66 (-3.00%)

As of 08/27/2026 07:59 PM Eastern

Compare

EXEL vs. NTRA, RVMD, BIIB, ALNY, and BNTX

Should you buy Exelixis stock or one of its competitors? Exelixis's main competitors and comparable companies include Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), and BioNTech (BNTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Exelixis compare to Natera?

Exelixis (NASDAQ:EXEL) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Exelixis currently has a consensus price target of $50.07, suggesting a potential downside of 9.40%. Natera has a consensus price target of $319.38, suggesting a potential downside of 5.71%. Given Natera's stronger consensus rating and higher probable upside, analysts clearly believe Natera is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

Exelixis has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.90	$782.57M	$3.18	17.38
Natera	$2.31B	21.17	-$208.16M	-$1.36	N/A

In the previous week, Natera had 22 more articles in the media than Exelixis. MarketBeat recorded 47 mentions for Natera and 25 mentions for Exelixis. Exelixis' average media sentiment score of 1.34 beat Natera's score of 1.28 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	20 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Natera	36 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Positive

Exelixis has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Natera has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market.

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 2.6% of Exelixis shares are owned by company insiders. Comparatively, 5.1% of Natera shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Exelixis has a net margin of 35.33% compared to Natera's net margin of -7.11%. Exelixis' return on equity of 42.17% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Natera	-7.11%	-11.38%	-7.87%

Summary

Natera beats Exelixis on 9 of the 17 factors compared between the two stocks.

How does Exelixis compare to Revolution Medicines?

Exelixis (NASDAQ:EXEL) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

Exelixis has a net margin of 35.33% compared to Revolution Medicines' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Revolution Medicines	N/A	-88.20%	-57.85%

Exelixis currently has a consensus price target of $50.07, suggesting a potential downside of 9.40%. Revolution Medicines has a consensus price target of $193.28, suggesting a potential downside of 12.60%. Given Exelixis' higher possible upside, equities analysts clearly believe Exelixis is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

Exelixis has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

In the previous week, Revolution Medicines had 20 more articles in the media than Exelixis. MarketBeat recorded 45 mentions for Revolution Medicines and 25 mentions for Exelixis. Exelixis' average media sentiment score of 1.34 beat Revolution Medicines' score of 0.91 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	20 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	27 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	3 Very Negative mention(s)	Positive

Exelixis has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.90	$782.57M	$3.18	17.38
Revolution Medicines	$11.58M	4,093.38	-$1.13B	-$8.82	N/A

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Exelixis beats Revolution Medicines on 9 of the 17 factors compared between the two stocks.

How does Exelixis compare to Biogen?

Biogen (NASDAQ:BIIB) and Exelixis (NASDAQ:EXEL) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

87.9% of Biogen shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Biogen had 13 more articles in the media than Exelixis. MarketBeat recorded 38 mentions for Biogen and 25 mentions for Exelixis. Exelixis' average media sentiment score of 1.34 beat Biogen's score of 1.23 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	29 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	20 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

Biogen currently has a consensus target price of $227.79, suggesting a potential upside of 2.84%. Exelixis has a consensus target price of $50.07, suggesting a potential downside of 9.40%. Given Biogen's stronger consensus rating and higher possible upside, analysts clearly believe Biogen is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30

Exelixis has a net margin of 35.33% compared to Biogen's net margin of 8.32%. Exelixis' return on equity of 42.17% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Exelixis	35.33%	42.17%	31.76%

Biogen has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.31	$1.29B	$5.65	39.20
Exelixis	$2.32B	5.90	$782.57M	$3.18	17.38

Summary

Biogen beats Exelixis on 9 of the 16 factors compared between the two stocks.

How does Exelixis compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Exelixis (NASDAQ:EXEL) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Exelixis has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Exelixis is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.52	$313.75M	$5.38	43.97
Exelixis	$2.32B	5.90	$782.57M	$3.18	17.38

Alnylam Pharmaceuticals presently has a consensus price target of $386.14, suggesting a potential upside of 63.23%. Exelixis has a consensus price target of $50.07, suggesting a potential downside of 9.40%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Alnylam Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30

In the previous week, Alnylam Pharmaceuticals had 2 more articles in the media than Exelixis. MarketBeat recorded 27 mentions for Alnylam Pharmaceuticals and 25 mentions for Exelixis. Exelixis' average media sentiment score of 1.34 beat Alnylam Pharmaceuticals' score of 1.18 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	21 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	20 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

Exelixis has a net margin of 35.33% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Exelixis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Exelixis	35.33%	42.17%	31.76%

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 2.6% of Exelixis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Alnylam Pharmaceuticals beats Exelixis on 11 of the 17 factors compared between the two stocks.

How does Exelixis compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Exelixis (NASDAQ:EXEL) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Exelixis has a net margin of 35.33% compared to BioNTech's net margin of -63.54%. Exelixis' return on equity of 42.17% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Exelixis	35.33%	42.17%	31.76%

BioNTech currently has a consensus target price of $127.81, suggesting a potential upside of 14.73%. Exelixis has a consensus target price of $50.07, suggesting a potential downside of 9.40%. Given BioNTech's stronger consensus rating and higher probable upside, equities research analysts plainly believe BioNTech is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30

15.5% of BioNTech shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 2.6% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Exelixis has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	8.68	-$1.29B	-$7.83	N/A
Exelixis	$2.32B	5.90	$782.57M	$3.18	17.38

In the previous week, Exelixis had 11 more articles in the media than BioNTech. MarketBeat recorded 25 mentions for Exelixis and 14 mentions for BioNTech. Exelixis' average media sentiment score of 1.34 beat BioNTech's score of 0.05 indicating that Exelixis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Exelixis	20 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market.

Summary

Exelixis beats BioNTech on 9 of the 16 factors compared between the two stocks.

Get Exelixis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EXEL vs. The Competition

Export

Metric	Exelixis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.90B	$4.04B	$7.32B	$12.78B
Dividend Yield	N/A	3.62%	2.53%	11.03%
P/E Ratio	17.38	11.26	271.29	25.71
Price / Sales	5.90	1,425.95	643.60	106.82
Price / Cash	18.53	108.46	79.17	53.57
Price / Book	7.43	16.47	13.01	6.26
Net Income	$782.57M	-$22.76M	$3.46B	$348.07M
7 Day Performance	2.18%	1.99%	0.98%	0.47%
1 Month Performance	-2.21%	13.04%	8.59%	5.19%
1 Year Performance	45.80%	59.10%	26.54%	16.68%

Exelixis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EXEL Exelixis	3.3485 of 5 stars	$55.26 -1.5%	$50.07 -9.4%	+43.5%	$13.90B	$2.32B	17.38	1,077	Positive News Options Volume Analyst Revision
NTRA Natera	2.708 of 5 stars	$336.71 +2.7%	$319.38 -5.1%	+107.7%	$48.53B	$2.71B	N/A	6,140	Positive News
RVMD Revolution Medicines	2.5335 of 5 stars	$211.40 -0.1%	$167.89 -20.6%	+481.4%	$45.31B	$11.58M	N/A	250	Trending News Analyst Forecast Insider Trade
BIIB Biogen	3.5183 of 5 stars	$220.77 +1.2%	$227.79 +3.2%	+62.4%	$32.62B	$9.89B	39.07	7,500	Positive News Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.7882 of 5 stars	$240.08 +1.7%	$386.14 +60.8%	-47.9%	$32.13B	$3.71B	44.62	2,770	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EXEL) was last updated on 8/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exelixis (EXEL) Competitors